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Introduction: Hypothalamic hypopituitarism is relatively rare cause of secondary adrenal deficiency which is often
accompanied by severe hypoglycemia. Hydrocortisone replacement therapy is essential for this condition, but
gastrointestinal symptom such as nausea and vomiting is not well-recognized adverse effect of hydrocortisone.
Case description: A 64-year-old-woman was referred to our hospital because of frequent severe hypoglycemia.
She was diagnosed as type 2 diabetes when she was 58 years old but had not been treated since she was 60. We
ruled out the possibility of exogenous administration of insulin or other anti-diabetic drugs, insulinoma and insulin
autoimmune syndrome. After glucose injection, she once became conscious, but severe hypoglycemia was often
observed even after that. In addition, counter-regulatory hormone levels were not increased even at the time of
hypoglycemia. We conducted several hormone load tests. In corticotropin-releasing hormone (CRH) load test, excess
and delayed reaction of ACTH was observed. In thyrotropin-releasing hormone (TRH) load test, TSH and prolactin
were normally secreted in response to TRH. In luteinizing hormone-releasing hormone (LHRH) load test, delayed
reaction of LH and FSH was observed. Based on such hormone loading tests, we diagnosed this patient as idiopathic
hypothalamic hypopituitarism and consequent adrenal deficiency. We immediately intravenously injected hydrocortisone
and started oral hydrocortisone therapy. However, just after taking hydrocortisone, vomiting was often observed which
disturbed sufficient steroid hormone replacement, leading to recurrent hypoglycemia. Therefore, we stopped
hydrocortisone and instead started an alternative treatment with prednisolone. After that, vomiting and
hypoglycemia were not observed at all.
Discussion and Evaluation: We diagnosed this subject as hypothalamic hypopituitarism mainly by the following
two findings: (1) excess and delayed reaction of ACTH in CRH load test, (2) delayed reaction of LH and FSH in
LHRH load test.
Conclusions: We should be aware of the possibility of hypothalamic hypopituitarism as a cause of recurrent severe
hypoglycemia. Also, we should be aware that hydrocortisone could induce gastrointestinal symptom and that in such
a case we should stop hydrocortisone and start prednisolone to sufficiently replace steroid hormone and avoid
recurrent hypoglycemia.
Keywords: Hypothalamic hypopituitarism; Hypoglycemia; Hydrocortisone* Correspondence: s.kamei@med.kawasaki-m.ac.jp
Division of Diabetes, Metabolism and Endocrinology, Kawasaki Medical
School, 577 Matsushima, Kurashiki 701-0192, Japan
© 2015 Takai et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly credited.
Table 1 Laboratory findings on admission
RBC 441 × 104 /μl TP 7.4 g/dl CRP 0.13 mg/dl
Hb 13.0 g/dl Alb 4.3 g/dl Total chol 169 mg/dl
WBC 8030 /μl Glb 3.1 g/dl TG 102 mg/dl
Neu 65.0 % T-bil 0.5 mg/dl HDL chol 36 mg/dl
Eos 5.4 % AST 28 IU/l LDL chol 109 mg/dl
Baso 0.6 % ALT 51 IU/l FPG 115 mg/dl
Mono 6.6 % γ-GTP 12 IU/l IRI 1.1 μU/ml
Lymph 22.4 % LDH 496 IU/l C-peptide 3.8 ng/ml
plt 34.6 × 104 /μl ALP 399 IU/l HbA1c 5.4%
Na 140 mEq/l ChE 35 IU/l GA 12.1%
K 3.9 mEq/l Cre 0.47 mg/dl anti-insulin Ab 3.8%
Cl 103 mEq/l BUN 8 mg/dl anti-GAD Ab <1.3 U/ml
Ca 9.2 mg/dl UA 3.8 mg/dl urine protein <10 mg/dl
P 3.2 mg/dl Amy 17 U/l urine albumin 20.3 mg/gCr
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It is well known that hypoglycemia is induced by various
reasons such as the overuse of anti-diabetic drugs
and/or insulin, various diseases including insulinoma,
insulin autoimmune syndrome and adrenal insufficiency.
Hypoglycemia influences quality of life and increases the
risk of cardiovascular events (Frier et al. 2011; Barendse
et al. 2012). When subjects suffer from hypoglycemia,
they usually notice it with warning symptoms such as cold
sweating and/or palpitation, but recurrent hypoglycemia
can lead to the impairment of counter-regulatory hor-
mone response and awareness of hypoglycemia which
sometimes leads to life-threatening hypoglycemic
coma (Widom and Simonson 1992; Kinsley et al. 1995;
Lingenfelser et al. 1995; Kaneto et al. 1998). Hypothal-
amic hypopituitarism is relative rare cause of adrenal
deficiency. Consequent adrenal deficiency is often ac-
companied by severe hypoglycemia. Hydrocortisone
replacement therapy is essential for this condition, but
gastrointestinal symptom such as nausea and vomiting
is not well-recognized adverse effect of hydrocortisone.
Here we report the case of hypothalamic hypopituitarism
accompanied by recurrent severe hypoglycemia.
Case report
Here we report the case of a 64-year-old-woman with
hypothalamic hypopituitarism accompanied by recurrent
severe hypoglycemia. She was diagnosed as type 2 dia-
betes in the preoperative examination prior to cataract
surgery when she was 58 years old. After then she was
treated with insulin for two years, but she did not use
any anti-diabetic drugs since she was 60. Since she had
experienced severe hypoglycemia many times, she was
referred to our hospital to examine the pathogenesis of
severe hypoglycemia. On admission, her body weight
was 58.9 kg and height was 145cm (Body Mass Index
was 28.0 kg/m2). There was no abnormality in the chest
and abdomen and no pretibial pitting edema. She had
no history of traumatic head injury. Furthermore, she
had no history of risky jobs and the martial arts, espe-
cially boxing and full contact Karate. Blood pressure was
155/71 mmHg and pulse rate was 88 bpm. Neurologic
examination showed no abnormality. She did not have
visual disturbance and headache. Deep tendon reflex
was normal in bilateral lower extremities. Tables 1 and 2
show the laboratory findings on admission. HbA1c was
5.4%, and fasting plasma glucose was 115 mg/dl. Serum
insulin level was 1.1 μU/ml, and anti-insulin antibody
was 3.8%. Electrolytes, whole blood count, renal and
liver function were normal (Table 1). In addition, there
was no findings that made us suspect any malignancy,
auto-immune and/or inflammatory disease (Table 2).
Based on these findings, we ruled out the possibility of
exogenous administration of insulin or other anti-diabeticdrugs, insulinoma and insulin autoimmune syndrome.
After glucose injection, she once became conscious, but
severe hypoglycemia was often observed even after that.
In addition, counter-regulatory hormone levels were not
increased even at the time of hypoglycemia (Table 3).
To explore the pathogenesis of severe hypoglycemia,
we performed several examination. First, magnetic res-
onance imaging (MRI) of the brain showed no obvious
abnormalities; pituitary abnormality such as adenoma
and pituitary stalk interruption was not observed. Sec-
ond, we conducted several hormone load tests (Figure 1).
In corticotropin-releasing hormone (CRH) load test, ex-
cess and delayed reaction of ACTH (adrenocorticotropic
hormone) was observed, indicating the dysfunction of
the hypothalamus. In thyrotropin-releasing hormone
(TRH) load test, TSH and prolactin were normally se-
creted in response to TRH. In luteinizing hormone-
releasing hormone (LHRH) load test, delayed reaction of
LH and FSH (follicle stimulating hormone) was ob-
served, which was also compatible with the possible dys-
function of the hypothalamus. Furthermore, in arginine
load test, GH reaction was very poor, which strengthened
the idea that the hypothalamus in this subject does not
function well. Based on these findings, we diagnosed this
subject as hypothalamic hypopituitarism although its
cause remained unknown. In growth hormone-releasing
hormone (GHRH) load test, GH reaction was poor. Al-
though the results in this GHRH load test suggest the pos-
sibility of adult GH deficiency, serum IGF-1 (insulin-like
growth factor-1) level was within normal range. Therefore,
we followed up without any medication for this poor GH
response.
To treat this hypothalamic hypopituitarism and conse-
quent adrenal deficiency, we intravenously injected hydro-
cortisone (100 mg) and started oral hydrocortisone therapy
Table 2 Laboratory findings on admission
ACTH 29.5 pg/ml TSH 4.19 μΙU/ml CEA 3.4 ng/ml
cortisol 8.9 μg/dl FT3 2.92 pg/ml CA19-9 18 U/ml
plasma renin activity 1.7 ng/ml/h FT4 0.76 ng/dl CA125 19.9 U/ml
aldosterone 55.7 pg/ml anti-Tg Ab 25.2 U/ml AFP 3.1 ng/ml
DHEA-S 123 μg/dl anti-TPO Ab 9.6 U/l PIVKA-II 23 mAU/ml
LH 24.0 mU/ml TRAb 1.6 U/l DUPAN ≤25U/ml
FSH 66.9 mU/ml TSAb 140% SPAN-1 7.5 U/ml
PRL 18.1 ng/ml anti-nuclear antibody (-) CYFRA ≤1.0 ng/ml
GH 0.09 ng/ml pituitary cell antibody (-) SCC 0.9 ng/ml
somatomedin C 114 ng/ml IgG4 <3.0 mg/dl ProGRP 46.5 pg/ml
adrenaline 23 pg/ml 1,25-(OH)2 vitaminD 63.4 pg/ml QFT (-)
noradrenaline 240 pg/ml urine Na 42 mEq/l Tb Ab <0.05 U/ml
dopamine 15 pg/ml urine K 13 mEq/l ACE 12.3 U/l
CMV pp65 Ab (-)
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vomiting was often observed. Since gastrointestinal symp-
tom was not common adverse effect of hydrocortisone, we
suspected the acute gastric ulcer and/or gastritis. Then we
performed the gastroesophageal endoscopy, but no abnor-
malities was found. Therefore, we continued to try to re-
place steroid hormone with hydrocortisone. However, it
seemed that such repeated vomiting disturbed sufficient
steroid hormone replacement, leading to recurrent
hypoglycemia. Several days later, we gave up the therapy
with hydrocortisone and instead started an alternative
treatment with prednisolone (15 mg/day) to replace ster-
oid hormone. After that nausea and vomiting disappeared
and hypoglycemia was not observed at all.Discussion and evaluation
In this report, we showed the subject with hypothalamic
hypopituitarism which was diagnosed based on the fol-
lowing findings: excess and delayed reaction of ACTH inTable 3 Various counter-regulatory hormone levels at the
time of hypoglycemia
PG (mg/dl) 42 36
IRI (μU/ml) <1.0 <1.0
C-peptide (ng/ml) 0.1 0.1
glucagon (pg/ml) 75 117
ACTH (pg/ml) 16.4 10.9
cortisol (μg/dl) 4.6 5.6
GH (ng/ml) 0.59 1.09
adrenaline (pg/ml) 40 40
noradrenaline (pg/ml) 287 489
dopamine (pg/ml) 17 41CRH load test, delayed reaction of LH and FSH in
LHRH load test, poor GH reaction in arginine load test.
Although we understood that it would be important to
perform insulin tolerance test in order to reconfirm the
dysfunction of the hypothalamus in this subject, we
failed to obtain the agreement from this subject about
the insulin load test due to the risk of the occurrence of
hypoglycemia. It was reasonable that this subject was
very afraid of the occurrence of hypoglycemia because
she experienced severe hypoglycemia repeatedly. There-
fore, we decided not to perform insulin tolerance test in
this subject. The GH releasing hormone + arginine
(GHRH +ARG) test is the best method to accurately
evaluate GH secretion. However, according to the Japanese
guideline for adult GH deficiency (The hypothalamic-pitu-
itary dysfunction study group of the Ministry of Health
Labour and Welfare, Japan 2009), we performed arginine
load test without GHRH. Therefore GH response should
be considered as low because of insufficient stimulation of
GH secretion. However, based upon the other various find-
ings, we thought that such recurrent severe hypoglycemia
in this subject was presumably due to hypothalamic
hypopituitarism.
We ruled out the possibility of malignancy, sarcoid-
osis, tuberculosis and traumatic injury, all of which
could be the reason for hypothalamic hypopituitarism
(Sharma and Sharma 1991; Saito et al. 2009; Greco 2012;
Glezer and Bronstein 2012), and thus we thought that
the hypothalamic hypopituitarism in this subject was
idiopathic. In addition, counter-regulatory hormone levels
were not increased even at the time of hypoglycemia
(Table 3). We think that this was presumably due to recur-
rent hypoglycemia as previously reported (Widom and
Simonson 1992; Kinsley et al. 1995; Lingenfelser et al.
1995; Kaneto et al. 1998).
Figure 1 Corticotropin-releasing hormone (CRH) load test: after intravenous injection of CRH (0.1 mg), ACTH and cortisol levels were
examined. Thyrotropin-releasing hormone (TRH) load test: after intravenous injection of TRH (0.5 mg), TSH and PRL levels were examined. Luteinizing
hormone-releasing hormone (LHRH) load test: after intravenous injection of LHRH (0.1 mg), LH and FSH levels were examined. Arginine load test: after
intravenous injection of arginine (10%, 300ml), GH level was examined. Growth hormone releasing hormone (GHRH) load test: after intravenous injection
of GHRH (0.1 mg), GH level was examined.
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and vomiting is not common adverse effect of hydro-
cortisone. In addition, prednisolone (15 mg/day) is
stronger than hydrocortisone (10 mg/day). Therefore,
we cannot exclude the possibility that the gastrointes-
tinal symptom in this subject was due to adrenal in-
sufficiency during the hydrocortisone treatment and
that the administration of prednisolone improved
adrenal insufficiency which led to the disappearance
of gastrointestinal symptom. However, considering
the situations that nausea and vomiting appeared
just after taking hydrocortisone, we think it is likely
that such gastrointestinal symptom is the adverse ef-
fect of hydrocortisone although its mechanism remains
unknown.
Conclusions
We should be aware of the possibility of hypotha-
lamic hypopituitarism as a cause of recurrent severe
hypoglycemia. In addition, although gastrointestinal
symptom is not common adverse effect of hydrocorti-
sone, we should be aware that hydrocortisone could in-
duce several gastrointestinal symptom such as nausea
and/or vomiting. Such symptom disturbs sufficient ster-
oid hormone replacement and leads to recurrent
hypoglycemia. Therefore, in such a case we should stop
hydrocortisone and instead start an alternative treatmentwith prednisolone without any hesitation in order to suf-
ficiently replace steroid hormone and to avoid recurrent
hypoglycemia.
Consent
Informed consent was obtained from this patient for
being included in the case report.
Statement of Human and Animal Rights
All procedures followed were in accordance with the
ethical standards of the responsible committee on
human experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as revised
in 2008 (Lingenfelser et al. 1995).
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